title: Expression of Bcl-2 and Bax in advanced or metastatic prostate carcinoma.
abstract: OBJECTIVE
  To evaluate the correlation of Bcl-2 and Bax protein expressions with biochemical failure-free survival in patients with advanced or metastatic prostate carcinoma (PCa) undergoing androgen deprivation therapy.
  
  
  METHODS
  This retrospective study was performed on patients with locally advanced (≥ T3) or metastatic PCa, who were referred to Omid Hospital between years 2003 and 2007. All subjects had undergone androgen deprivation therapy. Samples were analyzed immunohistochemically for Bax and Bcl-2 expression. The H-score was calculated for each sample based on intensity and percentage of stained cells. H-score > 50 was considered positive.
  
  
  RESULTS
  Thirty-seven patients (13 metastatic and 24 locally advanced) were eligible for analysis. Thirty-six (97.3%) samples were positive for Bax and 26 (70.3%) for Bcl-2 expression. The median H-score for Bax and Bcl-2 was 200 (range, 40 to 300) and 85 (range, 0 to 220), respectively. While there was no correlation between Bax expression and Gleason score, high Bcl-2 expression (H-score > 85) was significantly associated with Gleason score > 7 (P = .004). The median time to progression in the advanced and metastatic groups was 22 (range, 10 to 37) months and 16 (range, 9 to 26) months, respectively. High Bcl-2 expression (P = .01) and prostate-specific antigen > 20 ng/mL (P = .01) were significant predictors of lower biochemical progression-free survival.
  
  
  CONCLUSIONS
  High Bcl-2 expression was associated with higher Gleason scores and lower biochemical-free survival in patients with advanced PCa undergoing androgen deprivation therapy.
authors.affiliation: Cancer Research Center, Department of Radiotherapy Oncology, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Kazem
authors.initials: K
authors.lastname: Anvari
authors.forename: Mehdi
authors.initials: M
authors.lastname: Seilanian Toussi
authors.forename: Mahmoud
authors.initials: M
authors.lastname: Kalantari
authors.forename: Shahram
authors.initials: S
authors.lastname: Naseri
authors.forename: Mahdi
authors.initials: M
authors.lastname: Karimi Shahri
authors.forename: Hassan
authors.initials: H
authors.lastname: Ahmadnia
authors.forename: Mehrdad
authors.initials: M
authors.lastname: Katebi
authors.forename: Abdolazim
authors.initials: A
authors.lastname: Sedighi Pashaki
authors.forename: Mahdieh
authors.initials: M
authors.lastname: Dayani
authors.forename: Maryam
authors.initials: M
authors.lastname: Broumand
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002277:Carcinoma / Q000378:metabolism* / Q000556:secondary / Q000628:therapy; D016009:Chi-Square Distribution; D018450:Disease Progression; D018572:Disease-Free Survival; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009919:Orchiectomy; D016016:Proportional Hazards Models; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D012189:Retrospective Studies; D013997:Time Factors; D051028:bcl-2-Associated X Protein / Q000378:metabolism*
chemical_list: D000726:Androgen Antagonists; C494826:BAX protein, human; D014408:Biomarkers, Tumor; D019253:Proto-Oncogene Proteins c-bcl-2; D051028:bcl-2-Associated X Protein; D007987:Gonadotropin-Releasing Hormone; D017430:Prostate-Specific Antigen